Curative Biotechnology, Inc. https://curativebiotech.com/ Curative Biotech (CUBT) is a development-stage biomedical company focused on novel treatments for rare diseases with eight (8) programs in three (3) different therapeutic areas. Curative Biotechnology - Novel Solutions for Unmet Medical Needs CUBT is targeting therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of Curative Biotech is a product development engine that rests on its unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.)
Curative Biotech is a development-stage biomedical company focusing on novel treatments for rare diseases. Curative Biotech is focused on therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.):
Have world class science and sustainable intellectual property behind them.
Can be acquired opportunistically at favorable valuations.
Lend themselves to an accelerated approval pathway.
Address unmet medical needs for rare diseases only.
Authorized Shares 1,100,000,000 12/4/2020
Outstanding Shares 322,800,327
Restricted 99,336,588 12/4/2020
Unrestricted 223,463,739 12/4/20
Held at DTC 215,207,258 12/4/20
Chart: OTC Profile: https://www.otcmarkets.com/stock/CUBT/profile Official PR: Connectyx Technologies Holdings Group announces Shareholder Update March 06, 2020 09:30 ET | Source: Connectyx Technologies Holdings Group, Inc BOCA RATON, FL, March 06, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group (OTC PINK: CTYX) issued a shareholder update today regarding recent corporate developments including management and Board of Director changes. SunMed Advisors, LLC has recently acquired majority control of CTYX through the purchase of Series A Preferred stock from the two principal holders of CTYX. Jon Pevzner, former President and Director, has resigned and Paul M. Michaels was appointed Interim CEO and Director. Mr. Michaels has business and investment experience in Japan and the U.S. with noteworthy expertise in the Life Sciences sector. He has completed transactions involving companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead Sciences. Dr. Barry A. Ginsberg and Brandon Michaels join Mr. Michaels on the Board. CTYX is currently in the process of updating financials to become compliant with OTCMarkets and has appointed Jonathan D. Leinwand, PA as Legal Counsel. CTYX will continue to update shareholders on a new business plan through news releases, website updates and OTCMarkets filings as the company moves forward. Investor Database for Future Press Releases and Industry Updates Interested investors and shareholders are invited to be added to the corporate e-mail database for corporate press releases and periodic industry updates by sending an e-mail to: email@example.com About SunMed Advisors, LLC ( https://sunmedadvisors.com/ ) SunMed Advisors is a Life Science and Technology consulting firm that helps create maximum corporate value with strategic initiatives and a leading advisor on Pre-Commercial and Commercial-Stage licensing deals. SunMed brings value to all stages of licensing transactions, from sourcing through closing.
This part of the IBOX is being managed by RiseandShine follow me on twitter https://twitter.com/Rise2ShineLife 25 year Investment Banker and Harvard Business Graduate Paul M Michaels is here!
PAUL M. MICHAELS
For the past two decades, Mr. Michaels has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead, to name just a few.
Paul has also provided financial leadership for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales and successfully licensed multiple drugs from Gilead (formerly Nexstar Pharmaceuticals). Throughout his tenure, he structured and closed major transactions that brought high-value products to the Japanese pharmaceutical market in addition to other corporate responsibilities that included overall evaluation of corporate asset values. Paul subsequently founded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., which is now one of Japan’s most profitable orphan drug companies. As President of the U.S. division and a co-Founder,he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.
Paul began his career as Co-Founder, Executive Vice President and Board Member of Global Capital Group, a publicly traded corporate finance firm on Wall Street where he structured, financed and advised transactions in multiple spaces utilizing a variety of financial vehicles including private placements and Initial Public Offerings.
He received his Bachelor’s degree from Tulane University and completed an HBX program from Harvard.
Paul has completed transactions that influenced companies such as Celgene Corporation.
Paul is responsible for opening up the Japanese market to US drug companies
Inabata Pharmaceuticals becomes a significant provider of pharmaceuticals and API and merges with Sumitomo Pharmaceuticals in 1983. Licensing activity begins in 1996 with Sumitomo Pharmaceuticals, through the negotiations of Investment Banker, Paul M. Michaels, licenses Ambisome and Danisome for the Asian marketplace from a U.S. Pharmaceutical company. This is the beginning of business licensing U.S. developed drugs for the Japanese market. Additionally, an Orphan drug business is created with the assistance of Paul M. Michaels with his Japanese counterparts called Nobelpharma. Co.Ltd. The first licensed product, from Teva Pharmaceuticals USA, is for the treatment of Wilson's disease in Japan. This transaction was negotiated and completed by Paul Michaels.